Nov 5, 2021 Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
Nov 3, 2021 Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Oct 19, 2021 Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
Oct 14, 2021 Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Sep 20, 2021 Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
Aug 6, 2021 Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
Aug 6, 2021 Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
Jul 22, 2021 Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 20, 2021 Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
